Patient Characteristics
| . | Controls (n = 26) . | G-CSF (n = 25) . |
|---|---|---|
| Male/female | 17/9 | 10/15 |
| Age (yr) | ||
| Mean | 41.6 | 40.3 |
| Median | 41.7 | 36.4 |
| Range | 16-79 | 17-75 |
| ECOG status | ||
| 0-1 | 24 | 22 |
| 2 | 2 | 3 |
| WBC at diagnosis (×103/μL) | ||
| Mean | 22.8 | 31.0 |
| Median | 9.6 | 13.7 |
| Range | 1.9-124 | 1.1-171 |
| Immunophenotype | ||
| Early B-precursor | 5 | 5 |
| C-ALL | 12 | 11 |
| Pre-B | 5 | 2 |
| T-ALL | 4 | 7 |
| BCR/ABL rearrangement | 7/25 (28%) | 2/24 (8%) |
| Translocation (4;11) | 0/17 (0%) | 3/19 (16%) |
| . | Controls (n = 26) . | G-CSF (n = 25) . |
|---|---|---|
| Male/female | 17/9 | 10/15 |
| Age (yr) | ||
| Mean | 41.6 | 40.3 |
| Median | 41.7 | 36.4 |
| Range | 16-79 | 17-75 |
| ECOG status | ||
| 0-1 | 24 | 22 |
| 2 | 2 | 3 |
| WBC at diagnosis (×103/μL) | ||
| Mean | 22.8 | 31.0 |
| Median | 9.6 | 13.7 |
| Range | 1.9-124 | 1.1-171 |
| Immunophenotype | ||
| Early B-precursor | 5 | 5 |
| C-ALL | 12 | 11 |
| Pre-B | 5 | 2 |
| T-ALL | 4 | 7 |
| BCR/ABL rearrangement | 7/25 (28%) | 2/24 (8%) |
| Translocation (4;11) | 0/17 (0%) | 3/19 (16%) |
BCR/ABL rearrangement was determined by molecular analysis and translocation (4;11) by cytogenetic analysis. There was no statistically significant (P > 0.05) difference between both arms with regard to any of the patient characteristics given.